Maygace Altas Dosis

Megestrol acetate, the active ingredient in Maygace Altas Dosis, is a progestin presented as an oral tablet for oral use. It is employed to stimulate appetite and as hormonal therapy in patients with cachexia associated with AIDS or cancer, and in certain hormone‑sensitive cancers.

GNH USA supplies Maygace Altas Dosis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable delivery across global markets through established distribution networks and after‑sales support.

Maygace Altas Dosis (megestrol acetate) is used in the management of conditions involving hormonal modulation and appetite stimulation.

Cachexia associated with AIDS: improves appetite and promotes weight gain in patients with AIDS‑related wasting. Cachexia in cancer patients: helps increase caloric intake and stabilise body weight during oncologic therapy. Advanced breast cancer: provides antineoplastic activity in hormone‑responsive tumors. Endometrial cancer: used as hormonal therapy for disease control.

Megestrol acetate may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea or vomiting - Weight gain and fluid retention - Fatigue or weakness - Menstrual irregularities or amenorrhea - Mild hyperglycemia - Edema of the lower extremities

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Adrenal insufficiency or cortisol suppression - Severe hyperglycemia or new‑onset diabetes - Allergic reactions including rash or anaphylaxis - Cushingoid syndrome with characteristic fat redistribution

When prescribing Maygace Altas Dosis, clinicians should consider several safety measures.

Monitor weight and nutritional status: assess effectiveness and adjust therapy as needed. Assess thromboembolic risk: avoid use in patients with active clotting disorders. Evaluate blood glucose: monitor diabetic patients closely for hyperglycemia. Review hormone‑sensitive tumor status: consider alternative therapies if disease progresses. Adjust dose in hepatic impairment: use lower doses and monitor liver function. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Megestrol acetate can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase drug exposure. - Anticoagulants (e.g., warfarin): heightened risk of thrombosis. - Insulin or oral hypoglycemics: risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - Systemic corticosteroids: additive risk of fluid retention and hyperglycemia.